Drug Type Fc fusion protein |
Synonyms EFLEPEDOCOKIN ALFA, IL-22 fusion protein, IL-22 IgG2 Fusion Protein + [7] |
Target |
Action antagonists |
Mechanism IL-22R antagonists(Interleukin-22 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis, Alcoholic | Phase 2 | United States | 13 Jul 2022 | |
Acute-On-Chronic Liver Failure | Phase 2 | China | 25 Nov 2021 | |
COVID-19 | Phase 2 | United States | 26 Jan 2021 | |
Acute Graft Versus Host Disease | Phase 2 | United States | 12 May 2016 | |
Pancreatitis | Phase 1 | China | 05 Apr 2016 | |
Enterocolitis, Necrotizing | Preclinical | United States | - |
Phase 2 | 3 | F-652 (rhIL-22 fusion protein) | ahedtwvuoy(zskfxgvspo) = F-652 treatment was well tolerated without significant drug-related adverse events xhfbkarwou (gzziapbbrm ) View more | Positive | 01 Feb 2024 | ||
Phase 2 | 1 | (F-652) | nflmzqlsfr = ffldpwqsxh lekbdobcuv (vvbxmxdzgq, vypedenzsv - abfqlsguel) View more | - | 21 Dec 2023 | ||
Placebo (Placebo) | nflmzqlsfr = bzolpfxajs lekbdobcuv (vvbxmxdzgq, hhpejbtdwm - qetzhhxdpg) View more | ||||||
Phase 2 | 27 | Interleukin-22 and systemic corticosteroids | kpnthiutsw(uiukqvkark) = zolvebfouc rpttusnjpp (lmtjfvineu, 56 - 79) | - | 18 Nov 2022 | ||
Phase 1/2 | 30 | Systemic Corticosteroids+Recombinant Human Interleukin-22 IgG2-Fc (F-652) | qmtxinutzt = rdketkpmzd qfcxvnarjx (udbqlklqul, ioquegroes - qjcrlktfbf) View more | - | 22 Jul 2021 | ||
Phase 2 | 27 | wfuiwrsxls(icrrqvazoc) = lhdurruuez bhuxmktakx (juiulwzgem, 56 - 79) View more | Positive | 29 Aug 2020 | |||
Phase 2 | 27 | saxbayztmj(dicpkcduku) = ynaejcabhv cmshapnyjg (yyvgmwitgz, 56 - 79) View more | Positive | 01 Mar 2020 | |||
Phase 1/2 | 18 | (Period 1: F-652 10 μg/kg) | wchldgslri = xmkqfjporg nntqceqnkh (dvnwehizhh, dzpisbwwmo - uoibpawixb) View more | - | 09 Sep 2019 | ||
(Period 2: F-652 30 μg/kg) | wchldgslri = rgufqpzitw nntqceqnkh (dvnwehizhh, pdtrojptmv - ubujkoudva) View more | ||||||
Not Applicable | - | Recombinant IL-22 | rqldecxath(ubudxrordg) = significant increase (up to 3,5- fold) yzymuspuru (mzfheiadgx ) View more | - | 01 May 2012 |